Lightstone Ventures

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system.

Bonito Biosciences is a biotechnology research firm specializing in tissue-selective drug delivery for oligonucleotides and macromolecules.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Shoulder Innovations, Inc. is a medical device company based in Holland, Michigan, specializing in orthopedic solutions for shoulder replacement surgery. Founded in 2009, the company has developed an advanced Total Shoulder Replacement System that features innovative inset glenoid fixation technology, addressing the critical issue of glenoid implant stability during shoulder arthroplasty. This technology not only enhances the robustness of the glenoid platform but also simplifies the surgical instrumentation, aiming to reduce operative time and costs. The company's products are marketed through distribution partners in the United States and are designed to improve patient outcomes by minimizing the risk of glenoid loosening, which is a leading cause of revision surgeries. By focusing on reliable fixation and simplified surgical techniques, Shoulder Innovations strives to enhance the efficacy and longevity of shoulder implants while potentially lowering overall healthcare costs.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Volta Medical is a technology company based in Marseille, France, founded in 2016, that specializes in developing artificial intelligence software for interventional cardiology. The company focuses on aiding cardiologists in the treatment of atrial fibrillation, the most common cardiac arrhythmia. Volta Medical's flagship product utilizes advanced AI algorithms to analyze electrograms and guide mapping catheters during cardiac procedures. This software assists interventional cardiologists by providing real-time insights and step-by-step guidance, enhancing their ability to make informed decisions during patient-specific medical interventions. The company aims to improve the effectiveness of cardiac procedures and the overall management of atrial fibrillation through innovative technological solutions.

Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

ProVerum Medical is a medtech company focused on developing innovative minimally invasive devices for the treatment of benign prostatic hyperplasia (BPH). The company's technology offers a safer and more patient-friendly alternative to traditional BPH treatments, allowing patients to receive care in either a doctor's office or an operating room. ProVerum's device is designed to address the symptoms of prostate enlargement, which can lead to difficulties in urination. By placing the device inside the urethra, it aims to restore normal urinary function, ultimately enabling healthcare providers to deliver effective treatment options for patients suffering from this condition.

Choiceform is a user experience platform that specializes in online questionnaires, data collection, and analysis. It offers a Software as a Service (SaaS) platform designed to facilitate survey and market research services. By employing an innovative online survey model, Choiceform enables firms to gather comprehensive and accurate data, which supports informed decision-making in various sectors, including market research, consulting, advertising, and marketing. Through its services, the company aims to enhance the quality of data collection and analysis, driving better outcomes for its clients.

Vigil Neuroscience Inc is a therapeutics company focused on developing treatments for both rare and common neurodegenerative diseases by targeting microglia, the brain's immune cells. The company aims to restore the vigilance of these cells to improve patient outcomes. Vigil is advancing its lead candidate, a monoclonal antibody TREM2 agonist, through Phase 1 clinical studies, while also working on VG-3927, an orally available small molecule TREM2 agonist. These efforts are part of a broader strategy to build a robust pipeline of therapies supported by the understanding of microglia biology as a critical therapeutic pathway. Vigil's clinical candidate, iluzanebart, is currently undergoing a Phase 2 proof-of-concept trial in patients with ALSP, marking a significant step in the company's commitment to precision-based neuroscience drug development.

WayCool is an agri-tech company focused on the processing, distribution, and procurement of fresh produce, dairy products, and staples. By utilizing innovative quality management and food safety technology, WayCool enhances farmers' incomes and streamlines logistics and distribution services. The company sources fruits and vegetables primarily from smallholder farmers and aggregators, distributing them to local shops, retail outlets, hotels, restaurants, and catering establishments. WayCool operates a retail brand called SunnyBee in Chennai, which includes physical stores, mobile stores on trucks, and e-commerce platforms. Additionally, SunnyBee offers a range of high-quality private label products developed through partnerships with sister companies. By establishing direct connections between farmers and consumers, WayCool effectively integrates physical and information technology to facilitate efficient distribution of fresh produce.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.

Ligature Therapeutics is an early-stage biotechnology company focused on developing small molecule therapeutics that target protein degradation to address intractable diseases. Founded by doctors Alvin Hung, Thomas Keller, and Congbao Kang, the company employs a proprietary Fragment-Based Drug Discovery platform to enhance the efficiency of drug development. This innovative approach allows Ligature Therapeutics to identify and match underutilized, tumor-selective E3 ligases with specific cancer target proteins. By leveraging this technology, the company aims to provide effective treatments for challenging cancers and other difficult-to-treat conditions.

Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing innovative treatments for inherited retinal diseases. The company focuses on therapies for conditions such as X-linked retinoschisis and GUCY2D-associated Leber congenital amaurosis. Utilizing an advanced adeno-associated virus (AAV) technology platform, including a novel spreading capsid, Atsena aims to target specific retinal conditions to prevent blindness resulting from genetic mutations. Their research is centered on providing effective ocular gene therapies that address significant challenges associated with inherited retinal diseases, with the goal of reversing or halting vision loss.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Tallac Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. Founded in 2018 and headquartered in Burlingame, California, the company specializes in creating conjugates of antibodies combined with potent toll-like receptor agonists. This approach aims to activate both innate and adaptive immunity, enabling targeted immune responses against various solid tumor malignancies. Through its advanced therapies, Tallac Therapeutics seeks to enhance the immune system's ability to combat cancer more effectively.

Catamaran Bio, Inc. is a biotechnology company focused on developing allogeneic CAR-NK immune cell therapies for the treatment of solid tumors and other cancers. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes its Tailwind platform to engineer, expand, and process natural killer (NK) cells into off-the-shelf CAR-NK cell therapy products. By leveraging genetic engineering, Catamaran Bio aims to address significant unmet medical needs in cancer treatment, providing transformative therapies for patients.

Shoulder Innovations, Inc. is a medical device company based in Holland, Michigan, specializing in orthopedic solutions for shoulder replacement surgery. Founded in 2009, the company has developed an advanced Total Shoulder Replacement System that features innovative inset glenoid fixation technology, addressing the critical issue of glenoid implant stability during shoulder arthroplasty. This technology not only enhances the robustness of the glenoid platform but also simplifies the surgical instrumentation, aiming to reduce operative time and costs. The company's products are marketed through distribution partners in the United States and are designed to improve patient outcomes by minimizing the risk of glenoid loosening, which is a leading cause of revision surgeries. By focusing on reliable fixation and simplified surgical techniques, Shoulder Innovations strives to enhance the efficacy and longevity of shoulder implants while potentially lowering overall healthcare costs.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

Alchemab Therapeutics Ltd is a biotechnology company based in London, United Kingdom, focusing on the discovery and development of novel therapeutics aimed at patients with hard-to-treat diseases. Established in 2019 by Uri Laserson and Jane Osbourn, the company utilizes a transformative approach to identify drug targets and build a pipeline of antibody therapeutics. Alchemab's strategy involves harnessing naturally protective antibodies through an unbiased and function-first methodology that employs complementary processes and technologies. This innovative approach aims to provide treatments for various challenging conditions, including hard-to-treat cancers, neurodegenerative disorders, and infectious diseases.

Willow, founded in 2014 and based in Mountain View, California, is a company that specializes in the development and manufacturing of wearable breast pumps and related breastfeeding products. The company offers a range of items including in-bra breast pumps, milk bags, replacement parts, pumping bras, and accessories like flanges and chargers. Willow's breast pumps are designed to be mobile and hands-free, allowing mothers to pump discreetly and conveniently. The devices are cordless, spill-proof, and equipped with a mobile application that tracks milk output, facilitating a hassle-free pumping experience for mothers on the go.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Ummeed Housing Finance Private Limited is a housing finance company based in Gurugram, India, established in 2016. The company specializes in providing home loans and loans against property specifically tailored for lower and middle-income families in India, many of whom have limited access to organized financial services. By focusing on customers with informal incomes, Ummeed Housing Finance aims to bridge the gap in affordable housing finance. Its services include home loans, loans for construction, home renovation, and insurance options, all designed to enhance operational efficiency and reduce turnaround times. The company leverages technology to deliver personalized and accessible financial solutions, thereby supporting the aspirations of low and middle-income households in securing affordable housing.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Willow, founded in 2014 and based in Mountain View, California, is a company that specializes in the development and manufacturing of wearable breast pumps and related breastfeeding products. The company offers a range of items including in-bra breast pumps, milk bags, replacement parts, pumping bras, and accessories like flanges and chargers. Willow's breast pumps are designed to be mobile and hands-free, allowing mothers to pump discreetly and conveniently. The devices are cordless, spill-proof, and equipped with a mobile application that tracks milk output, facilitating a hassle-free pumping experience for mothers on the go.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Bold Penguin is a commercial insurance exchange that connects customers, agents, and carriers to match the right quote in record time. With a heavy focus on the agents, Bold Penguin pushes the boundaries of user experience for businesses, an easy tool for agents, and a streamlined process of underwriting for carriers. The company operates an Exchange which utilizes a set of solutions to identify, triage, quote, and bind commercial insurance in a highly efficient and tech-enabled way. It plans to deliver on the platform enhancements which include more flexibility in how the core technology is leveraged by enterprise customers, expanding in excess and surplus lines. The Company offers a streamlined process of underwriting for carriers in commercial property and casualty insurance services. Bold Penguin was founded in 2016 and is headquartered in Columbus, Ohio, USA.

Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Nuvaira, Inc. is a medical device company based in Minneapolis, Minnesota, focused on developing innovative treatments for obstructive lung diseases, particularly chronic obstructive pulmonary disease (COPD). Founded in 2008, Nuvaira specializes in a novel catheter-based Lung Denervation System that aims to address airway nerve hyperactivity by targeting the parasympathetic innervation of the lungs. This minimally invasive procedure is designed to improve lung function, enhance exercise capacity, and elevate the quality of life for patients suffering from chronic respiratory conditions. With a commitment to advancing treatment options, Nuvaira seeks to reduce the clinical consequences associated with neural hyperactivity in conditions such as COPD and asthma.

Allay Therapeutics is focused on developing innovative solutions for post-surgical pain management, aiming to enhance patient recovery experiences. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutics. These products are designed to deliver targeted pain relief over extended periods, significantly surpassing the duration of existing pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical study for total knee arthroplasty surgeries. With a diverse team of entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics seeks to address the limitations of conventional pain management approaches, particularly the challenges associated with opioid use.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Relievant Medsystems, Inc. is a medical device company focused on developing innovative solutions for chronic axial low back pain. Founded in 2004 and headquartered in Minneapolis, Minnesota, with a development office in Sunnyvale, California, the company has created the Intracept System. This minimally invasive procedure specifically targets the basivertebral nerve, providing relief by blocking pain signal transmission. The Intracept System offers patients a low-risk therapy option aimed at alleviating chronic vertebrogenic low back pain.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Medisix Therapeutics is a Singapore-based immune engineering company developing novel cellular therapies to address T cell malignancies. Their technology platform originates from world expert in translational immunology, Professor Dario Campana, MD, PhD, a physician scientist who pioneered chimeric antigen receptor T cell (CAR-T) biology. Their programs utilize proprietary immune engineering approaches that enable T cell leukemias and lymphomas to be targeted with cell therapy.

Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative therapies based on DNA repair biology for cancer treatment and synthetic lethality in autoimmune diseases. Founded in 2012 and headquartered in Lexington, Massachusetts, the company focuses on precision targeting of critical DNA repair factors to induce self-destruction in diseased cells through an overload of DNA damage. Cyteir employs an integrated drug development platform that addresses the imbalance between DNA damage and repair, resulting in a pipeline of small molecule therapeutics aimed at various disease states, including hematological malignancies, solid tumors, and chronic autoimmune disorders. Its lead compound, CYT-0851, is an oral investigational drug designed to inhibit RAD51-mediated homologous recombination, targeting specific vulnerabilities in cancer cells.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Claret Medical, Inc. is a cardiovascular medical device company based in Santa Rosa, California, focused on developing cerebral vascular protection systems for transcatheter aortic valve implantation and other endovascular procedures. The company's flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris dislodged during these procedures, thereby reducing the risk of stroke. Additionally, Claret Medical offers small 6 French catheters that are inserted through an artery into the patient's right arm, guiding the system to the heart and effectively safeguarding the brain from embolic material during interventional procedures. Incorporated in 2009, Claret Medical aims to enhance patient safety and outcomes by preventing the entry of thrombus and debris into the cerebral vascular system during various cardiovascular interventions.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Allay Therapeutics is focused on developing innovative solutions for post-surgical pain management, aiming to enhance patient recovery experiences. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutics. These products are designed to deliver targeted pain relief over extended periods, significantly surpassing the duration of existing pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical study for total knee arthroplasty surgeries. With a diverse team of entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics seeks to address the limitations of conventional pain management approaches, particularly the challenges associated with opioid use.

Cerevance LLC is a biotechnology company focused on developing innovative therapeutics for neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and other chronic neurodegenerative conditions. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Cambridge, United Kingdom, the company utilizes its NETSseq platform to profile specific brain cell types, including neurons and glial cells, using a repository of over 15,000 human brain tissue samples. This platform provides detailed expression and epigenetic data, allowing Cerevance to identify promising therapeutic targets for central nervous system diseases. Through its research, the company aims to advance new medicines that can potentially address the underlying mechanisms of these debilitating conditions.

Carrick Therapeutics, Ltd. is a Dublin-based company founded in 2015 that specializes in the development of innovative cancer therapeutics. The company focuses on targeting molecular pathways associated with aggressive and resistant forms of cancer. By employing advanced mechanisms, Carrick Therapeutics aims to transform cancer treatment and improve patient outcomes. Their approach facilitates the early detection of predictive biomarkers, allowing for timely initiation of personalized treatments.

Gemini Therapeutics, Inc. is a precision medicine company based in Cambridge, Massachusetts, established in 2015. The company is dedicated to developing innovative therapies for patients with dry age-related macular degeneration (AMD) and related rare genetic diseases. Gemini Therapeutics focuses on genetically defined conditions, ensuring that their therapeutic candidates are tailored to the specific molecular abnormalities found in patients with significant clinical needs. Their extensive pipeline includes a range of modalities such as monoclonal antibodies, recombinant proteins, and gene therapies. Supported by prominent life science investors and global academic collaborations, Gemini Therapeutics aims to create potentially first-in-class therapeutics to address unmet medical needs in the field of ophthalmology.

Tizona Therapeutics, Inc. is a biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. Founded in 2014 and based in South San Francisco, California, the company is engaged in creating innovative treatments that target immunosuppressive cells and mechanisms within the tumor microenvironment. Its product pipeline includes an Anti-CCR4 antibody for cancer therapy, as well as IL-35 antagonists and agonists aimed at addressing both cancer and autoimmune conditions. Tizona is also collaborating with its scientific founders to investigate the role of regulatory T cells in various tumors, enhancing the understanding of their contribution to immunosuppression. This research aims to differentiate the company’s approach and improve patient outcomes by facilitating complete and lasting remissions.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets. Elcelyx is headquartered in San Diego, California.

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics for diseases linked to the excessive activation of the complement system. Utilizing a peptide chemistry platform, the company produces synthetic macrocyclic peptides that offer the specificity and diversity of antibodies alongside the pharmacological advantages of small molecules. Its lead product candidate, Zilucoplan, is an injectable treatment that has completed Phase II clinical trials for generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria, as well as a Phase Ib trial for patients with renal impairment. In addition to Zilucoplan, Ra Pharmaceuticals is advancing pre-clinical programs targeting Factor D inhibition for C3 glomerulonephritis and dense deposit disease, among other conditions. The company has also established a collaboration with Merck & Co., Inc. to explore orally available cyclic peptides for cardiovascular targets. Founded in 2008, Ra Pharmaceuticals operates as a subsidiary of UCB SA.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

Nimbus Therapeutics, LLC is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing innovative medicines for serious diseases, including metabolic disorders, cancer, and immune-inflammatory conditions. Founded in 2009, the company utilizes a computational technology-driven approach to advance a pipeline of novel small-molecule therapeutics. Nimbus Therapeutics specializes in designing allosteric inhibitors, notably targeting Acetyl-CoA Carboxylase for conditions such as non-alcoholic steatohepatitis and hepatocellular carcinoma. The company has established strategic partnerships with organizations like Charles River Laboratories and Celgene Corporation to enhance its drug development efforts. In March 2015, Nimbus Discovery rebranded itself as Nimbus Therapeutics to better reflect its transition into a clinical-stage enterprise.

ALX Oncology is a clinical-stage immuno-oncology company based in Burlingame, California, established in 2015. The company specializes in developing innovative therapies aimed at treating various forms of cancer, with a particular focus on its lead product candidate, ALX148. This therapeutic agent is designed to block the CD47 protein, which cancer cells exploit to evade the immune system. ALX148 is currently being investigated for its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and several solid tumor types, including head and neck squamous cell carcinoma and certain gastric cancers. The company leverages advanced protein engineering technologies to enhance the affinity of its CD47 blockers, aiming to minimize hematologic toxicities often associated with existing treatments. ALX Oncology's commitment to improving cancer therapies is rooted in pioneering research conducted by its founders at Stanford University.

Flex Pharma, Inc. is a biotechnology company focused on developing and commercializing innovative treatments for muscle cramps, spasms, and spasticity related to neurological conditions and exercise-associated muscle cramps. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates in two segments: Consumer Operations and Drug Development. Its lead drug candidate, FLX-787, is a dual transient receptor potential V1/A1 ion channel activator that has completed an exploratory Phase II clinical trial in Australia for patients with multiple sclerosis. Additionally, Flex Pharma offers HOTSHOT, a consumer beverage designed to prevent and treat exercise-associated muscle cramps, which is marketed through its direct-to-consumer website and third-party platforms. In 2019, Flex Pharma was acquired by Salarius Pharmaceuticals, marking a significant shift in its operational structure.

Claret Medical, Inc. is a cardiovascular medical device company based in Santa Rosa, California, focused on developing cerebral vascular protection systems for transcatheter aortic valve implantation and other endovascular procedures. The company's flagship product, the Claret Medical Sentinel Cerebral Protection System, is a percutaneously delivered embolic protection device designed to capture and remove debris dislodged during these procedures, thereby reducing the risk of stroke. Additionally, Claret Medical offers small 6 French catheters that are inserted through an artery into the patient's right arm, guiding the system to the heart and effectively safeguarding the brain from embolic material during interventional procedures. Incorporated in 2009, Claret Medical aims to enhance patient safety and outcomes by preventing the entry of thrombus and debris into the cerebral vascular system during various cardiovascular interventions.

Earlens is a medical technology company focused on improving the hearing experience for individuals with hearing loss. It has created the Earlens Contact Hearing Solution, a unique device that directly stimulates the eardrum using a small lens, replicating the natural hearing process. Unlike conventional hearing aids that amplify sound, the Earlens solution delivers sound directly to the eardrum, providing superior sound quality and a broader bandwidth. This innovative, non-surgical approach allows for automatic adjustments in challenging listening environments while minimizing feedback. The technology received FDA clearance in 2019 for its second generation, marking a significant advancement in hearing solutions aimed at enhancing the quality of life for those with hearing impairment.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Astria Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for patients affected by rare allergic and immunological diseases. The company focuses on creating life-changing treatments, with its lead program, STAR-0215, being a monoclonal antibody designed to inhibit plasma kallikrein, currently in preclinical development for hereditary angioedema. Additionally, Astria is advancing STAR-0310, another monoclonal antibody, which targets the OX40 receptor and is also in preclinical development for atopic dermatitis, a condition characterized by impaired skin barrier function and significant itching. Through its targeted approach, Astria Therapeutics aims to address unmet medical needs in the field of immunology.